From $25B to $55B: Moderna’s Melanoma Math
The Phase 3 win validated the platform. Now the harder work begins: manufacturing every dose from scratch.
The Phase 3 win validated the platform. Now the harder work begins: manufacturing every dose from scratch.
Three of this week’s biggest moves share one thread: the market is still deciding what each story is actually worth.
INTerpath-001 topline moved the stock 177% in one day. Hazard ratios, p-values, and survival curves were not released.
The headline is cooling. The real-wage deficit is where the consumer trade lives.
Ooredoo just committed $800M to Indonesia and Mubadala is weighing $6.3B in Japan. The Asia pivot is no longer a rumor.
Virginia’s SCC clock is running. A first-ever gubernatorial intervention landed this week. The arb math just got more complicated.
Astra is the first OpenAI system flagged at Critical cyber risk. The cybersecurity market is already pricing in what comes next.
Ullal’s promise to add one or two new 10%-plus revenue customers before year-end changes the concentration calculus entirely.
The Grand Sport X is the only hybrid GM sells in the U.S. That says more about electrification credibility than a dozen press releases.
Short interest at 34% of float, 911.5 million shares unlocking after earnings. The bears are not betting against the business.